alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 99.1

                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                       AS ADOPTED PURSUANT TO SECTION 906
                        OF THE SARBANES-OXLEY ACT OF 2002

      Each of the undersigned hereby certifies, in accordance with 18 U.S.C.
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in
his capacity as an officer of 4Kids Entertainment, Inc. (the "Company"), that,
to his knowledge, the Annual Report of the Company on Form 10-K for the period
ended December 31, 2002, fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934 and that the information
contained in such report fairly presents, in all material respects, the
financial condition and results of operations of the Company.

Date: March 31, 2003

                                   By: /s/ Alfred R. Kahn
                                       --------------------------------------
                                       Alfred R. Kahn
                                       Chairman of the Board and Chief
                                       Executive Officer

Date: March 31, 2003

                                   By: /s/ Joseph P. Garrity
                                       -----------------------------------------
                                       Joseph P. Garrity
                                       Executive Vice President and
                                       Chief Financial Officer

A signed original of this written statement required by Section 906 has been
provided to 4Kids Entertainment, Inc. and will be retained by 4Kids
Entertainment, Inc. and furnished to the Securities and Exchange Commission or
its staff upon request.
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.2840 Apex cardiographic transducer. ( a ) *Identification.* An apex cardiographic transducer is a device used to detect motion of the heart (acceleration, velocity, or displacement) by changes in the mechanical or electrical properties of the device.
( b ) *Classification.* Class II (performance standards).
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.6810 Tracheobronchial suction catheter. ( a ) *Identification.* A tracheobronchial suction catheter is a device used to aspirate liquids or semisolids from a patient's upper airway.
( b ) *Classification.* Class 1 (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 868.9.
[47 FR 31142, July 16, 1982, as amended at 65 FR 2314, Jan. 14, 2000]
EXHIBIT 32.2
                                                                    ------------

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of GVC Venture Corp. (the "Company") on
Form 10-QSB for the quarter ended December 31, 2003, as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I, Marc
Hanover, Principal Financial Officer of the Company, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002 that, to the best of my knowledge:

        (1)    The Report fully complies with the requirements of Section 13(a)
               or 15(d) of the Securities Exchange Act of 1934; and

        (2)    The information contained in the report fairly presents, in all
               material respects, the financial condition and results of
               operations of the Company.

Date: February 17, 2004

                                      /s/ Marc Hanover
                                      ------------------------------------------
                                      Marc Hanover
                                      Vice President, Finance and Treasurer
                                      (Principal Financial Officer and Principal
                                      Accounting Officer







                                       14
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5630 Nebulizer. ( a ) *Identification.* A nebulizer is a device intended to spray liquids in aerosol form into gases that are delivered directly to the patient for breathing. Heated, ultrasonic, gas, venturi, and refillable nebulizers are included in this generic type of device.
( b ) *Classification.* Class II (performance standards).
# C_2015354EN.01003701.xml

| 26.10.2015 | EN | Official Journal of the European Union | C 354/37 |
| --- | --- | --- | --- |

26.10.2015

EN

Official Journal of the European Union

C 354/37

---

Judgment of the General Court of 10 September 2015 — Laverana v OHIM (ORGANIC WITH PLANT FLUID FROM OUR OWN PRODUCTION)

(Case T-608/14) (1)

1

((Community trade mark - Application for Community figurative mark ORGANIC WITH PLANT FLUID FROM OUR OWN PRODUCTION - Absolute ground for refusal - Descriptive character - Article 7(1)(c) of Regulation (EC) No 207/2009))

(2015/C 354/44)

Language of the case: German

Parties

Parties

Applicant: Laverana GmbH & Co. KG (Wennigsen, Germany) (represented by: J. Wachinger, M. Zöbisch and D. Chatterjee, lawyers)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: D. Walicka and D. Botis, acting as Agents)

Defendant:

Re:

Re:

Action brought against the decision of the Fourth Board of Appeal of OHIM of 2 June 2014 (Case R 121/2014-4) concerning an application for registration of the figurative sign ORGANIC WITH PLANT FLUID FROM OUR OWN PRODUCTION as a Community trade mark.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Laverana GmbH & Co. KG to bear the costs. |
| --- | --- |

2.

Orders Laverana GmbH & Co. KG to bear the costs.

---

(1)  OJ C 361, 13.10.2014.

1

---
EXHIBIT 99.1














































<PAGE>


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



     In connection  with the Quarterly  Report of CEC  Entertainment,  Inc. (the
"Company")  on Form 10-Q for the quarter  ended March 30, 2003 as filed with the
Securities  and  Exchange  Commission  on the date  hereof (the  "Report"),  the
undersigned certify,  pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, that:


     (1)  The Report fully  complies with the  requirements  of Section 13(a) or
          15(d) of the Securities Exchange Act of 1934; and

     (2)  The  information  contained  in the  Report  fairly  presents,  in all
          material respects,  the financial  condition and results of operations
          of the Company.



                                            /s/ Richard M. Frank
                                            --------------------
                                            Richard M. Frank
                                            Chief Executive Officer
                                            May 13, 2003


                                            /s/ Rodney Carter
                                            -----------------
                                            Rodney Carter
                                            Chief Financial Officer
                                            May 13, 2003
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM FORM 10-QSB
FOR THE QUARTER ENDED SEPTEMBER 30, 1999 AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FORM 10-QSB.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                       1,193,098
<SECURITIES>                                   169,199
<RECEIVABLES>                                1,255,048
<ALLOWANCES>                                         0
<INVENTORY>                                    761,000
<CURRENT-ASSETS>                             3,619,259
<PP&E>                                       6,199,145
<DEPRECIATION>                               1,962,633
<TOTAL-ASSETS>                               7,862,021
<CURRENT-LIABILITIES>                          912,900
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     1,601,916
<OTHER-SE>                                   3,919,310
<TOTAL-LIABILITY-AND-EQUITY>                 7,862,021
<SALES>                                      5,894,493
<TOTAL-REVENUES>                             5,936,596
<CGS>                                        2,858,258
<TOTAL-COSTS>                                1,822,477
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              74,613
<INCOME-PRETAX>                              1,181,248
<INCOME-TAX>                                   457,554
<INCOME-CONTINUING>                            723,694
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   723,694
<EPS-BASIC>                                        .19
<EPS-DILUTED>                                      .19


</TABLE>
~ 

I
#### § 814.19 Product development protocol (PDP).

A class III device for which a product development protocol has been declared completed by FDA under this chapter will be considered to have an approved PMA.
§ 814.112 Filing an HDE. ( a ) The filing of an HDE means that FDA has made a threshold determination that the application is sufficiently complete to permit substantive review. Within 30 days from the date an HDE is received by FDA, the agency will notify the applicant whether the application has been filed. FDA may refuse to file an HDE if any of the following applies: ( 1 ) The application is incomplete because it does not on its face contain all the information required under § 814.104(b);
( 2 ) FDA determines that there is a comparable device available (other than another HUD approved under this subpart or a device under an approved IDE) to treat or diagnose the disease or condition for which approval of the HUD is being sought; or
( 3 ) The application contains an untrue statement of material fact or omits material information.
( 4 ) The HDE is not accompanied by a statement of either certification or disclosure, or both, as required by part 54 of this chapter.
( b ) The provisions contained in § 814.42(b), (c), and (d) regarding notification of filing decisions, filing dates, the start of the 75-day review period, and applicant's options in response to FDA refuse to file decisions shall apply to HDE's.
[61 FR 33244, June 26, 1996, as amended at 63 FR 5254, Feb. 2, 1998; 63 FR 59221, Nov. 3, 1998]
<PAGE>
 
                                 Exhibit 24(b)
                     Power of Attorney of Director Gammill



     KNOW ALL MEN BY THESE PRESENTS that the undersigned, a director of The
Guarantee Life Companies Inc., a Delaware corporation (the "Company"), hereby
appoints each of Robert D. Bates, Richard A. Spellman and Paul D. Ochsner as his
true and lawful attorney-in-fact to act for him and in his name and on his
behalf, individually and as a director of the Company, to sign one or more Form
10-K Annual Reports and Form 10-Q Quarterly Reports and any amendments thereto
and to file the same with the Securities and Exchange Commission and generally
to do and perform all things necessary to be done in connection with the
foregoing as fully in all respects as he could do personally.

     IN WITNESS WHEREOF, I have hereunto set my hand this 4th day of June, 1997.




                                            /s/ Lee M. Gammill, Jr          
                                            ---------------------------------
                                            Lee M. Gammill, Jr.

STATE OF NEW YORK         )
                          )  SS.
COUNTY OF NEW YORK        )


     The undersigned, being a notary public in and for the above county and
state, does hereby state that before me appeared Lee M. Gammill, Jr., being
personally known to me, who, being first duly sworn, did acknowledge that the
foregoing Power of Attorney was executed by him and that such execution was his
free act and deed.



                                            /s/ Dirk S. Levinsohn
                                            ---------------------------------
                                            Notary Public
My Commission Expires:

8/26/98                 (SEAL)
-------
Electronically FiledIntermediate Court of AppealsCAAP-11-000010624-SEP-201211:55 AM
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.7695 Platelet factor 4 radioimmunoassay. ( a ) *Identification.* A platelet factor 4 radioimmunoassay is a device used to measure the level of platelet factor 4, a protein released during platelet activation by radioimmunoassay. This device measures platelet activiation, which may indicate a coagulation disorder, such as myocardial infarction or coronary artery disease.
( b ) *Classification.* Class II (performance standards).
[45 FR 60625, Sept. 12, 1980; 46 FR 14890, Mar. 3, 1981]
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.3930 Bone grafting material. ( a ) *Identification.* Bone grafting material is a material such as hydroxyapatite, tricalcium phosphate, polylactic and polyglycolic acids, or collagen, that is intended to fill, augment, or reconstruct periodontal or bony defects of the oral and maxillofacial region.
( b ) *Classification.* ( 1 ) Class II (special controls) for bone grafting materials that do not contain a drug that is a therapeutic biologic. The special control is FDA's “Class II Special Controls Guidance Document: Dental Bone Grafting Material Devices.” (See § 872.1(e) for the availability of this guidance document.)
( 2 ) Class III (premarket approval) for bone grafting materials that contain a drug that is a therapeutic biologic. Bone grafting materials that contain a drug that is a therapeutic biologic, such as biological response modifiers, require premarket approval.
( c ) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
[70 FR 21949, Apr. 28, 2005]
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.5550 Immunoglobulin (light chain specific) immunological test system. ( a ) *Identification.* An immunoglobulin (light chain specific) immunological test system is a device that consists of the reagents used to measure by immunochemical techniques both kappa and lambda types of light chain portions of immunoglobulin molecules in serum, other body fluids, and tissues. In some disease states, an excess of light chains are produced by the antibody-forming cells. These free light chains, unassociated with gamma globulin molecules, can be found in a patient's body fluids and tissues. Measurement of the various amounts of the different types of light chains aids in the diagnosis of multiple myeloma (cancer of antibody-forming cells), lymphocytic neoplasms (cancer of lymphoid tissue), Waldenstrom's macroglobulinemia (increased production of large immunoglobulins), and connective tissue diseases such as rheumatoid arthritis or systemic lupus erythematosus.
( b ) *Classification.* Class II (performance standards).
# C_2016314EN.01002001.xml

| 29.8.2016 | EN | Official Journal of the European Union | C 314/20 |
| --- | --- | --- | --- |

29.8.2016

EN

Official Journal of the European Union

C 314/20

---

Judgment of the General Court of 19 July 2016 — Alpha Calcit v EUIPO — Materis Paints Italia (CALCILITE)

(Case T-742/14) (1)

1

((EU trade mark - Invalidity proceedings - EU figurative mark CALCILITE - Earlier EU word mark Calcilit - Relative ground for refusal - Likelihood of confusion - Similarity of the goods - Article 8(1)(b) and Article 53(1)(a) of Regulation (EC) No 207/2009 - Relevant public - Public common to the goods in question))

(2016/C 314/27)

Language of the case: English

Parties

Parties

Applicant: Alpha Calcit Füllstoffgesellschaft mbH (Cologne, Germany) (represented by: F. Hauck, lawyer)

Applicant:

Defendant: European Union Intellectual Property Office (represented by: S. Palmero Cabezas, acting as Agent)

Defendant:

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Materis Paints Italia SpA (Novate Milanese, Italy) (represented by: P.L. Roncaglia, F. Rossi and N. Parrotta, lawyers)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court:

Re:

Re:

Action brought against the decision of the Fourth Board of Appeal of EUIPO of 4 September 2014 (Case R 753/2013-4), relating to invalidity proceedings between Alpha Calcit Füllstoffgesellschaft and Materis Paints Italia.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Annuls the decision of the Fourth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 4 September 2014 (Case R 753/2013-4) as regards the ‘paints, varnishes, lacquers; preservatives against rust and against deterioration of wood; colorants; mordants’ covered by the contested trade mark; |
| --- | --- |

1.

Annuls the decision of the Fourth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 4 September 2014 (Case R 753/2013-4) as regards the ‘paints, varnishes, lacquers; preservatives against rust and against deterioration of wood; colorants; mordants’ covered by the contested trade mark;

| 2. | Dismisses the action as to the remainder; |
| --- | --- |

2.

Dismisses the action as to the remainder;

| 3. | Orders Alpha Calcit Füllstoffgesellschaft mbH, EUIPO and Materis Paints Italia SpA to bear their own costs. |
| --- | --- |

3.

Orders Alpha Calcit Füllstoffgesellschaft mbH, EUIPO and Materis Paints Italia SpA to bear their own costs.

---

(1)  OJ C 462, 22.12.2014.

1

---
Electronically Filed Supreme Court SCPW-12-0000014 12-JAN-2012 12:52 PM

NO. SCPW-12-0000014 IN THE SUPREME COURT OF THE STATE OF HAWAI ' I DR. ORLY TAITZ, Petitioner,
vs. THE HONORABLE RHONDA A. NISHIMURA, JUDGE OF THE CIRCUIT ' COURT OF THE FIRST CIRCUIT, STATE OF HAWAI I, Respondent.
ORIGINAL PROCEEDING ORDER (By: Recktenwald, C.J., Nakayama, Acoba, Duffy, and McKenna, JJ.) Upon consideration of petitioner Dr. Orly Taitz's petition for a writ of mandamus, it appears that petitioner fails to demonstrate an entitlement to mandamus relief. See Kema v. Gaddis , 91 Hawai ' i 200, 204, 982 P.2d 334, 338 (1999) (A writ of mandamus is an extraordinary remedy that will not issue unless the petitioner demonstrates a clear and indisputable right to relief and a lack of alternative means to redress adequately the alleged wrong or obtain the requested action. Such writs are not intended to supersede the legal discretionary authority of the lower courts, nor are they intended to serve as legal remedies in lieu of normal appellate procedures. ). Accordingly,IT IS HEREBY ORDERED that the petition for a writ of mandamus is denied. DATED: Honolulu, Hawai ' i, January 12, 2012. /s/ Mark E. Recktenwald /s/ Paula A. Nakayama /s/ Simeon R. Acoba, Jr. /s/ James E. Duffy, Jr. /s/ Sabrina S. McKenna

2
<Page>

                                                                  Exhibit 10.23


                     AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT

     This agreement (this "Amendment No. 2") amends certain provisions of the
Employment Agreement dated as of January 1, 2000, as amended by Amendment No. 1
dated as of December 1, 2000 (the "Employment Agreement"), by and between
Apropos Technology, Inc., an Illinois corporation (the "Company"), and Kevin G.
Kerns (the "Employee").

     The words "six (6) months" in Section 7(a)(i) of the Employment Agreement
are hereby replaced with the words "twelve (12) months".

     The Employment Agreement shall remain in full force and effect except as
expressly amended hereby. This Amendment No. 2 shall by governed by and
construed in accordance with the laws of the State of Illinois, without regard
to the conflict of law rules of such State. This Amendment No. 2 may be executed
in one or more counterparts, each of which shall be deemed an original and all
of which, together, shall constitute one and the same instrument.

     Agreed, accepted to and made effective this 7th day of November, 2002,
being the date this Amendment No. 2 was approved by the Compensation Committee
of the Board of Directors of the Company.

APROPOS TECHNOLOGY, INC.

By: /s/ George Koch
    ------------------------
    Member of the Compensation Committee
    of the Board of Directors of the Company


/s/ Kevin G. Kerns
----------------------------
Kevin G. Kerns
### D ISTRICT 

### C OURT 

### O F 

### A PPEAL 

### O F 

### T HE 

### S TATE 

### O F 

### F LORIDA
F OURTH D ISTRICT

EUGENE MILTON , Appellant,

v.

STATE OF FLORIDA , Appellee

.

No. 4D 17

- 1956

[ August 31, 2017 ]

Appeal of order denying rule 3.850 motion from the Circuit Court for the Seventeenth Judicial Circuit, Broward County ; Michael I. Rothschild

, Judge; L.T. Case No. 08

- 21359 CF10A

.
Eugene Milton, Indiantown, pro se.

No appearance required for appellee.

P ER C URIAM

.
Affirmed.

G ROSS , K LINGENSMITH and K UNTZ , JJ., concur.

* * *

Not final until disposition of timely filed motion for rehearing.